Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI helps Non-Experts perform heart scans in rare heart condition

NCT ID NCT07155434

Knowledge-focused Sponsor: UltraSight Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether healthcare workers without ultrasound training could use AI software to perform heart scans on people with hypertrophic obstructive cardiomyopathy (HOCM) who are eligible for the drug mavacamten. Participants had two scans on the same day: one by a non-specialist using the AI guidance and one by a trained sonographer. The goal was to see if the AI-assisted scans were good enough to monitor heart function, potentially making it easier for patients to get regular check-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
UltraSight AI guidance software
What this could lead to
If successful, this could allow more patients to get heart scans without needing a specialist, making monitoring easier and more accessible.
What could go wrong
This was a small, terminated study, so results may not be reliable. AI-guided scans may not match the quality of trained sonographers, limiting real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

36 people

The number who actually took part.

Started

Jul 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hypertrophic obstructive cardiomyopathy (HOCM) patients eligible for mavacamten (Camzyos™) treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female subjects aged 18 years or over at the time of screening. 2. Willing and able to give written informed consent. 3. New York Heart Association (NYHA) Class I to III 4. Eligible to receive or currently receiving CamzyosTM per product labelling. Exclusion Criteria: 1. Emergency (non-elective) admission within 24 hours prior to participating in the study. 2. Unable to lie down as required in all the classic positions for standard TTE exam: supine on back/left decubitus. 3. Subjects who had technically difficult exam in the past, due to body habitus, upon investigator's discretion. 4. Subjects with body mass index (BMI) above 40 kg/m2. 5. Subjects experiencing a known or suspected acute cardiac event. 6. Subjects with severe chest wall deformities as per previous medical records and physical examination. 7. Subjects who have undergone pneumonectomy. 8. Subjects whose anatomy does not lend itself to yield diagnosable echocardiography clips (i.e., situs inversus with dextrocardia, single ventricle anatomy due to congenital heart defect, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac imaging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac imaging Echocardiography Hypertrophic cardiomyopathy (HCM) Mavacamten Obstructive cardiomyopathy, hypertrophic

Contacts and locations

Locations

  • Cleveland Clinic, Cardiovascular Medicine Department

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.